Figure 1From: Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled studyPatients with hepatocellular carcinoma and BCLC stage A. Median survival rates in long-acting octreotide [Sandostatin LAR], TACE, multimodal therapy and palliative care were 31.4, 37.3, 40.2 and 15.1 months respectively. Survival rates of patients with active treatment did not differ significantly.Back to article page